A number of other analysts have also weighed in on the company. TheStreet upgraded Omnicell from a c+ rating to a b rating in a research note on Thursday, October 24th. Sidoti set a $82.00 price target on shares of Omnicell and gave the stock a hold rating in a research report on Friday, October 25th. Dougherty & Co increased their price objective on shares of Omnicell from $90.00 to $92.00 and gave the stock a buy rating in a report on Thursday, November 21st. Finally, BidaskClub upgraded shares of Omnicell from a hold rating to a buy rating in a research report on Thursday, November 21st. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Omnicell has a consensus rating of Buy and an average price target of $83.00.
NASDAQ OMCL opened at $79.23 on Tuesday. The firm has a market cap of $3.35 billion, a PE ratio of 51.78, a price-to-earnings-growth ratio of 3.06 and a beta of 1.12. Omnicell has a one year low of $56.96 and a one year high of $92.59. The stock’s 50 day simple moving average is $75.35 and its 200 day simple moving average is $76.05. The company has a debt-to-equity ratio of 0.10, a current ratio of 2.09 and a quick ratio of 1.63.
In related news, CEO Randall A. Lipps sold 1,172 shares of the business’s stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $78.00, for a total transaction of $91,416.00. Following the completion of the sale, the chief executive officer now directly owns 128,487 shares of the company’s stock, valued at $10,021,986. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Dan S. Johnston sold 9,086 shares of the stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $80.38, for a total transaction of $730,332.68. Following the completion of the transaction, the executive vice president now owns 27,826 shares in the company, valued at $2,236,653.88. The disclosure for this sale can be found here. Over the last quarter, insiders sold 67,753 shares of company stock valued at $5,296,632. Corporate insiders own 2.77% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in OMCL. Invesco Ltd. lifted its stake in shares of Omnicell by 79.8% in the 2nd quarter. Invesco Ltd. now owns 779,632 shares of the company’s stock valued at $67,072,000 after purchasing an additional 346,029 shares during the period. BlackRock Inc. increased its holdings in Omnicell by 5.7% in the second quarter. BlackRock Inc. now owns 6,413,649 shares of the company’s stock valued at $551,764,000 after purchasing an additional 344,744 shares during the last quarter. Nuveen Asset Management LLC increased its holdings in Omnicell by 1,731.7% in the second quarter. Nuveen Asset Management LLC now owns 348,324 shares of the company’s stock valued at $29,966,000 after purchasing an additional 329,308 shares during the last quarter. Peregrine Capital Management LLC lifted its stake in Omnicell by 9,014.6% in the third quarter. Peregrine Capital Management LLC now owns 270,704 shares of the company’s stock valued at $19,564,000 after buying an additional 267,734 shares during the period. Finally, Vanguard Group Inc. lifted its stake in Omnicell by 4.6% in the second quarter. Vanguard Group Inc. now owns 4,223,552 shares of the company’s stock valued at $363,352,000 after buying an additional 186,781 shares during the period. 98.44% of the stock is owned by hedge funds and other institutional investors.
Omnicell Company Profile
Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.